Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria

O. M. Sandvik1,5, K. Søreide1,5, E. Gudlaugsson2, J. T. Kvåly3,4 and J. A. Søreide1,5

Departments of 1Gastrointestinal Surgery, 2Pathology and 3Research, Stavanger University Hospital, and 4Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, and 5Department of Clinical Medicine, University of Bergen, Bergen, Norway

Correspondence to: Professor J. A. Søreide, Department of Gastrointestinal Surgery, Stavanger University Hospital, PO Box 8100, N-4068 Stavanger, Norway (e-mail: jonarne.soreide@uib.no)

Background: The lack of uniform criteria for coding of gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) has hampered previous epidemiological studies. The epidemiology of GEP-NEN was investigated in this study using currently available criteria.

Methods: All patients diagnosed with GEP-NEN between January 2003 and December 2013 in a well defined Norwegian population of approximately 350 000 people were included. Age- and sex-adjusted incidence rates were calculated. The current 2010 World Health Organization criteria, European Neuroendocrine Tumour Society classification and International Union Against Cancer (UICC) classification were used.

Results: A total of 204 patients (114 male, 55.9 per cent) were identified. The median age at diagnosis was 61 (range 10–94) years. The annual overall crude incidence was 5.83 per 100 000 inhabitants, with an increasing trend (P = 0.033). The most frequent location was small intestine (60 patients, 29.4 per cent) followed by appendix (48 patients, 23.5 per cent) and pancreas (33 patients, 16.2 per cent). Grade 1 tumours were more common in gastrointestinal (100 patients, 58.5 per cent) than in pancreatic (9 patients, 27 per cent) NEN. According to the UICC classification, 77 patients (37.7 per cent) had stage I, 17 patients (8.3 per cent) stage II, 37 patients (18.1 per cent) stage III and 70 patients (34.3 per cent) had stage IV disease. No patient with stage I disease had grade 3 tumours; advanced tumour grade increased with stage.

Conclusion: A high crude incidence of GEP-NEN, at 5.83 per 100 000 inhabitants, was noted together with a significant increasing trend over time.

Presented in part to the 12th European Neuroendocrine Tumour Society Congress, Barcelona, Spain, March 2015; published in abstract form as Neuroendocrinology 2015; 102: 92

Paper accepted 17 September 2015
Published online 29 October 2015 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.10034

Introduction

Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) originates from the diffuse neuroendocrine cell system of the gastrointestinal tract and pancreas, and represents 1–1.5 per cent of all GEP neoplasms1,2. This heterogeneous group of epithelial neoplasms is highly variable in its clinical presentation, malignant potential and prognosis3.

In 1867, the neuroendocrine tumour (NET) was first described as a specific entity4. A system for tumour classification was initially developed5, but the nomenclature for this entity has been inconsistent. Numerous classification systems for staging and grading based on embryology, morphology or biochemistry have been proposed, with none gaining robust acceptance over time5–7.

The current 2010 World Health Organization (WHO) classification of GEP-NEN is based on histological grade and derived from degree of differentiation and the Ki-67 index, as proposed by the European Neuroendocrine Tumour Society (ENETS) in 2006 and 20078–10. Other characteristics, including tumour size and location and presence of metastases, are incorporated into the ENETS 2006–2007 TNM system8,9. In 2009, the International Union Against Cancer (UICC) published another TNM system for tumour staging11. By the introduction of a uniform nomenclature and classification system for
GEP-NEN, improved and comparable epidemiological data should eventually be available. In the past the epidemiology of GEP-NEN has been examined based on regional and national registries in Europe, the USA and Asia12–26.

To circumvent many of the shortcomings of previous studies regarding definitions and reporting, this cohort study evaluated the epidemiological characteristics of patients diagnosed with GEP-NEN based on the most recent WHO and ENETS/UICC classifications, using a population-based, single-institution, consecutive series of patients treated over a decade.

**Methods**

This manuscript was completed in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement27. The Hospital Review Board approved the study (2011/1659-16) according to the general guidelines provided by the Regional Ethics Committee.

**Population sample**

Stavanger University Hospital, as the only hospital in the region, serves a catchment area of 18 municipalities in south-western Norway. It provides healthcare services to a well defined population that has increased from approximately 290,000 inhabitants in 2003 to more than 350,000 in 201428. The study included all patients initially diagnosed with GEP-NEN in this region during the 11-year interval from 1 January 2003 to 31 December 2013. All permanent residents of Norway are assigned an 11-digit identification number in the National Population Registry. Any change of address must be reported to the National Population Registry within 8 days of moving. The hospital’s patient administrative system is linked electronically to the National Population Registry28, enabling continued contact for follow-up assessments.

**Identification of patients**

Eligible patients were identified through a review of all NEN diagnoses recorded in the hospital’s electronic pathology files. The data files were searched for histopathological or cytological diagnoses according to the Systematized Nomenclature of Medicine (SNOMED) classification system (Norwegian version) (topography T56/59/62-68; diagnosis M80411-3+6/M82401-6/ M82431-3/M82441-3/M82451/M82461-3+6). Neuroendocrine neoplasms of the gastrointestinal tract and pancreas were identified. Lesions with histomorphology and immunohistochemistry (IHC) profiles consistent with GEP-NEN were included. Where necessary, histology was re-evaluated, particularly with regard to the completeness of the IHC data (chromogranin A, synaptophysin, Ki-67, thyroid transcription factor 1 and CDX2, among others) and the proportion of different histological components in mixed adenoneuroendocrine carcinoma (MANEC).

Neuroendocrine liver tumours (labelled unknown) were included when an extrahepatic tumour outside the abdomen could be excluded via imaging or when the IHC profile did not suggest a primary lung tumour. All patients who underwent somatostatin receptor scintigraphy at the hospital during the study were reviewed to identify eligible patients with NEN not confirmed by histology. A search for eligible patients from the Stavanger University Hospital catchment area was also undertaken at a collaborating institution (Haukeland University Hospital, Bergen).

Patients diagnosed with primary non-gastrointestinal NEN, including lung, Merkel cell carcinomas, prostate, urinary bladder, uterus, breast, head and neck or otherwise misclassified tumours (by either location or histopathology), were excluded from the analysis.

Patient demographics and clinical information, including date of diagnosis, location of tumours and presence of regional and/or distant metastases, were retrieved from hospital records, autopsy reports, and information from general practitioners and the National Population Registry28. The tumour characteristics recorded were: size, mitotic count (per high-power field) and the expression of Ki-67 (in ‘hot spots’), synaptophysin and chromogranin A by IHC.

**Definitions**

The patients were grouped according to the 2010 WHO classification29 (Table 1), and staged according to the 2006–2007 ENETS8,9 and 2009 UICC11 criteria for TNM classification, for comprehensive and comparable reporting. In MANEC, both the high-grade neuroendocrine and the adenocarcinoma proportion exceed 30 per cent.

Annual age- and sex-adjusted incidence rates were calculated by direct standardization with 5-year intervals for age (with an open-ended interval from 85 years or more) using the World30, USA 200031, WHO32 and European 201333 standard populations, along with the Norwegian population (for each year) retrieved from Statistics Norway28, as references. The population size for each year was the calculated average of the population at the beginning and end of the year.
Table 1 2010 World Health Organization classification of gastroenteropancreatic neoplasia

| Mitoses (per 10 HPFs) | Ki-67 index |
|-----------------------|-------------|
| Neuroendocrine tumour |             |
| Grade 1 (carcinoid)   | < 2         | ≤ 2         |
| Grade 2               | 2–20        | 3–20        |
| Neuroendocrine carcinoma | > 20       | > 20        |
| Mixed adenoneuroendocrine carcinoma | Hyperplastic and preneoplastic lesions |

At least 50 high-power fields (HPFs) counted (2 mm², original magnification ×40). Ki-67 immunoreactivity evaluated in ‘hot spots’.

Statistical analysis

SPSS® version 22.0.0.0 for Mac (IBM, Armonk, New York, USA) and R3.1.0 (R Foundation for Statistical Computing, Vienna, Austria) were used for data analysis. Non-parametric tests were used for comparisons between subgroups, and log-linear Poisson regression analysis to test for differences in crude incidence over the study interval. To calculate age- and sex-adjusted incidence, the epitools package in R 3.1.0 was used.34. Additional rates were set to the standard population employed, the incidence remained high, and varied between a low annual crude incidence of 2.37 per 100 000 in 2004 to the highest incidence of 8.35 per 100 000 in 2009 (Fig. 1), with an increasing trend during the study period (P = 0.033).

Incidence by sex and time

The annual overall crude incidence was 5.83 per 100 000 inhabitants (6.47 and 5.19 per 100 000 for men and women respectively). Standardized directly to the Norwegian population, the annual incidence rate was 6.62 per 100 000 inhabitants, with rates of 7.41 and 5.83 per 100 000 for men and women respectively.

The annual adjusted incidence rates standardized for different populations are shown in Table 2. Regardless of the standard population employed, the incidence remained high, and varied between a low annual crude incidence of 2.37 per 100 000 in 2004 to the highest incidence of 8.35 per 100 000 in 2009 (Fig. 1), with an increasing trend during the study period (P = 0.033).

Men were more frequently diagnosed with small intestinal (P < 0.001) and duodenal (P = 0.011) NEN, whereas tumours of unknown origin were more frequently found in women (P = 0.004) (Table 2).

Incidence by location

Almost one-third of the primary tumours (60, 29.4 per cent) were located in the small intestine (excluding the duodenum but including 2 NETs in Meckel’s diverticulum), and the appendix was the second most common tumour.
Table 3  Incidence rates of gastroenteropancreatic neoplasia, with adjusted rates related to common reference populations

| Incidence (per 100,000 per year) | Crude | Norway | World | WHO | USA 2000 | Europe 2013 |
|----------------------------------|-------|--------|-------|-----|----------|-------------|
| All                             | 5.83  | 6.62   | 4.43  | 4.86| 5.68     | 7.64        |
| Male                            | 6.47  | 7.41   | 4.83  | 5.40| 6.15     | 9.08        |
| Female                          | 5.19  | 5.83   | 4.02  | 4.31| 5.23     | 6.20        |

WHO, World Health Organization.

Fig. 1  Annual incidence per 100,000 by year in the study period. Poisson regression analysis shows a statistically significant increase in the annual crude incidence ($P = 0.033$)

Fig. 2  World Health Organization tumour grade by organ. Of note is the wide variation in tumour grade between locations; low-grade tumours are most commonly encountered in the duodenum, small intestine and appendix

Tumour grade and stage at diagnosis

A total of 109 patients (53.4 per cent) had G1 NETs, 49 (24.0 per cent) had G2 NETs, and 40 (19.6 per cent) patients were diagnosed with G3 NEC. Male and female patients were distributed similarly across grades. The annual incidence rates for G1 tumours were 3.51 and 2.71 per 100,000 males and females respectively. For G2 tumours, respective rates for males and females were 1.53 and 1.27 per 100,000, and for G3 they were 1.30 and 0.98 per 100,000. Grade distribution for different locations is shown in Fig. 2. Grade 1 tumours were more common in gastrointestinal (100 patients, 58.5 per cent) than in pancreatic (nine patients, 27 per cent) NEN. All duodenal and appendiceal tumours, and most small intestinal (57 of 60), pancreatic (23 of 33) and rectal (12 of 18) tumours, showed G1/G2 differentiation. All three oesophageal NETs, a majority of the colonic NETs (11 of 15) and six of nine NETs with an unknown primary tumour site showed G3 differentiation. Four of the G3 NECs were classified as MANECs. Two appendiceal tumours were diagnosed as goblet cell carcinoids, which are currently regarded as a specific entity.35,36 This entity should no longer be classified as a NEN (ENETS, personal communication, 2015).

Half of patients (98, 48.0 per cent) had regional lymph node metastases, and more than one-third (70, 34.3 per cent) had distant organ metastases (liver, lung and distant lymph nodes) at the time of diagnosis. Ten of 15 patients with colonic NEN presented with distant organ metastases, whereas only one of the 48 patients with a primary appendiceal NEN had distant metastases. Regional lymph node involvement was present in most patients with NEN in the small intestine (52 of 60) and colon (12 of 15).

According to the UICC classification, 77 patients (37.7 per cent) had stage I, 17 patients (8.3 per cent) stage II, 37 patients (18.1 per cent) stage III and 70 patients (34.3 per cent) had stage IV disease. No patient with stage I disease had grade 3 tumours; advanced tumour grade increased with stage. The distribution of tumour site (48, 23.5 per cent) (Table 2). A sixth of the tumours (33, 16.2 per cent) originated in the pancreas, including three tumours in patients with multiple endocrine neoplasia type 1 syndrome (MEN-1).

Multiplicity, defined as primary NEN in two different organs, was found in three patients: in the duodenum and stomach in one patient, the small intestine and appendix in another, and the pancreas and duodenum in a third patient with MEN-1. Multifocal tumours in the small intestine were encountered in 21 (35 per cent) of 60 patients.
The observed discrepancy between the present findings together with the Swedish autopsy study and the overall reported incidence of GEP-NEN in the literature may have several explanations. Approximately 90 per cent of the neuroendocrine neoplasms identified in the Swedish autopsy study were previously undetected. Clearly, many patients with NEN are asymptomatic and remain undiagnosed, and these tumours may therefore be clinically insignificant. However, the clinical presentation of NETs is often non-specific, and the average delay from onset of symptoms to diagnosis is suggested to be between 5 and 7 years. An increased awareness of NEN among clinicians, radiologists and pathologists, together with widespread use of improved diagnostic tools (such as somatostatin receptor imaging, CT, endoscopies and specific IHC markers), has increased the number of patients with incidentally discovered NEN. These tumours may have gone undetected in the patient’s lifetime in the Swedish cohort. Demographic changes that include an ageing population might also contribute to this increase, because the frequency of NEN increases with age, as also shown here. Finally, the increased incidence has also been attributed in part to improved pathological classification; a greater proportion of previously undifferentiated carcinomas are now recognized as NECs.

A concern related to epidemiological figures from cancer registries (such as the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) database and the Cancer Registry of Norway) is that the recording of NEN is usually restricted to ‘malignant carcinoids’, thereby disregarding benign tumours and NEN with uncertain malignant potential, as noted by Hauso and colleagues. A rather low, although increasing, annual incidence of GEP-NEN of 2.38 per 100 000 (USA 2000; for interval 2000–2004), can be calculated from that study, explained mainly by under-reporting to the registry.

Data collection over long intervals introduces bias of disease definitions and classifications. A lower incidence of GEP-NEN is usually reported from other series. A French study found an annual age-adjusted (world) incidence rate associated with malignant digestive NEN (pancreatic lesions included) of 0.76 per 100 000 men and 0.50 per 100 000 women. The study had a higher median age and a smaller proportion of appendiceal tumours than the present investigation. Although an increasing incidence was observed (1976–1999), differences between these two studies can be explained mainly by the fact that the overall undergoing autopsy. Current autopsy rates in most countries are not comparable and make similar studies difficult.

The incidence of GEP-NEN obtained from south-western Norway is among the highest reported in the literature and increased significantly over the study interval. The present population-based study contributes to understanding of the true epidemiology of GEP-NEN. The increasing trend is in line with other studies from the USA and Europe. The high incidence reported in this study may seem an outlier. However, a previous Swedish autopsy study reported an annual incidence of 8.4 NETs per 100 000 inhabitants (including fewer than 10 per cent bronchial tumours), which represents a sevenfold increase from that recorded by the Swedish National Cancer Register over the same interval (1958–1969). These findings are also consistent with current understanding of the epidemiology of NEN, that there is likely to be a substantial discrepancy between clinically discovered lesions (those reported to a regional or national registry) and their true incidence (asymptomatic, non-diagnosed disease). The autopsy rate was high in the Swedish study, with 99 per cent of patients who died in hospital and 63 per cent in general undergoing autopsy.
that only malignant tumours were included in the French analysis. A prospective 1-year audit of GEP-NEN from Austria reported an annual age-adjusted incidence rate (USA 2000) of 2.99 per 100,000 inhabitants. Tumours were most frequently located in the stomach, whereas the small bowel was less commonly affected. Although the authors assumed a high degree of completeness of the data, one-quarter of the 41 institutions involved did not report any patients, suggesting possible detection bias. Finally, a study from the Netherlands Cancer Registry reported an age-standardized (with respect to European standardized rate) increase in the incidence of NEN from 2.1 in 1990 to 4.9 per 100,000 inhabitants in 2010. Although this supports an increasing incidence, the lower reported incidence is again likely to be explained by a reporting bias towards malignant disease.

The well defined, controlled sample and the centralized infrastructure of the healthcare system in the region serves as an excellent basis for epidemiological research, and is a strength of the present study. The present data obviously contrast with publications from tertiary referral centres, which have an inherent selection bias towards overt malignant and difficult-to-manage cases, which might impede data interpretation. Patient migration out of the region is minimal, which limits the influence of regional referral patterns, different treatment policies or patients diagnosed at other institutions. The most updated definitions and classifications of GEP-NEN have been used. To ensure appropriate comparison of incidence data, commonly used reference populations were employed.

Limitations of this study are the size of the population at risk, the retrospective design and the accrual period of 11 years. However, the transparent and controlled access to data in the study region is probably superior to collection of general data reported to a national registry. The period of 11 years should also allow fairly comparable diagnostic opportunities, whereas a longer lag time would potentially increase the variability in diagnostic approach.

Comparing the present high and increasing incidence of GEP-NEN in south-western Norway with recently published data from various regions, it is evident that appropriate identification and reporting of patients with NEN remain a challenge.

Acknowledgements

The authors thank E. Hoel of Statistics Norway, Oslo, for providing detailed demographic data on the Norwegian population during the study period. They are also indebted to the late Professor Michael Brauckhoff for providing pertinent data on some of the included patients, who were managed partially at Haukeland University Hospital, Bergen. This study was financed partly by an unrestricted research grant provided by CarciNor, the Norwegian patient advocacy association for NEN.

Disclosure: The authors declare no conflict of interest.

References

1. Lepage C, Bouvier AM, Faiyre J. Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours. Eur J Endocrinol 2013; 168: R77–R83.
2. Yao JC, Hassan M, Phan A, Dagogoy C, Leary C, Mares JE et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063–3072.
3. Kloppe G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014: 13–27.
4. Langhans T. Über einen Drüsenpolyp im Ileum. Archiv F Pathol Anat 1867; 38: 559–560.
5. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963; 1: 238–239.
6. Soga J, Tazawa K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 1971; 28: 990–998.
7. Pearse AG. The diffuse neuroendocrine system and the apud concept: related ‘endocrine’ peptides in brain, intestine, pituitary, placenta, and anuran cutaneous glands. Med Biol 1977; 55: 115–125.
8. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757–762.
9. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395–401.
10. Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Klöppel G et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In WHO Classification of Tumours of the Digestive System, Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). International Agency for Research on Cancer: Lyon, 2010; 13–14.
11. Sobin LH, Gospodarowicz MK, Wittekind C (eds). International Union Against Cancer (UICC). TNM Classification of Malignant Tumours (7th edn). Wiley-Blackwell: Oxford, 2009.
12. Westergaard T, Frisch M, Mølbym M. Carcinoid tumors in Denmark 1978–1989 and the risk of subsequent cancers. A population-based study. Cancer 1995; 76: 106–109.
13. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17: 909–918.
14 Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–97. Br J Cancer 2000; 83: 952–955.
15 Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, Faivre J. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004; 53: 549–553.
16 Lepage C, Bouvier AM, Manfredi S, Dancourt V, Faivre J. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol 2006; 101: 2826–2832.
17 Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40: 1–18, vii.
18 Landerholm K, Falkner S, Jarhult J. Epidemiology of small bowel carcinoids in a defined population. World J Surg 2010; 34: 1500–1505.
19 Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010; 45: 234–243.
20 Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 2015; 50: 58–64.
21 Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204–2210.
22 Faenkel M, Kim M, Faggiano A, de Herder WW, Valk GD, Knowledge N. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endor Relat Cancer 2014; 21: R153–R163.
23 Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010; 105: 2563–2569.
24 Crocetti E. Gastrointestinal carcinoid tumours. A population-based study. Ital J Gastroenterol Hepatol 1997; 29: 135–137.
25 Caldarella A, Crocetti E, Paci E. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol Oncol Res 2011; 17: 759–763.
26 Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A 1976; 84: 322–330.
27 von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandebroucke JP et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806–808.
28 Statistics Norway. http://www.ssb.no [accessed 20 October 2014].
29 Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011; 18(Suppl 1): S1–S16.
30 Doll R. Comparison between registries. Age-standardized rates. In Cancer Incidence in Five Continents, Waterhouse J, Muir C, Correa P, Powell P (eds). International Agency on Cancer: Lyon, 1976; 453–459.
31 Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. Healthy People 2010 Stat Notes 2001; (20): 1–10.
32 Ahmad OB, Boschi-Pinto C, Lopez A, Murray CJ, Lozano R, Inoue M. Age Standardization of Rates: a New WHO Standard. World Health Organization: Geneva, 2001.
33 Eurostat European Commission. Revision of the European Standard Population: Report of Eurostats Task Force; 2013. http://ec.europa.eu/eurostat/documents/3859598/5926869/KS-RA-13-028-EN.PDF?etargetState=7133aa79-1add-44e8-b234d-5e8fa9bb3bf [accessed 30 September 2015].
34 Aragon TJ (developer). EpiTools: Epidemiology Tools. R package version 0.5–7; 2012. http://CRAN.R-project.org/package=epitools [accessed 30 September 2015].
35 Holt N, Grönvik H. Goblet cell carcinoids of the appendix. Scientific World Journal 2013; 2013: 543696.
36 Roy P, Chetty R. Goblet cell carcinoid tumors of the appendix: an overview. World J Gastrointest Oncol 2010; 2: 251–258.
37 Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer 2013; 49: 1975–1983.
38 van der Zwan JM, Trama A, Larrañaga N, Tavilla A, Marcos-Gragera R et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer 2013; 49: 2565–2578.
39 Burton JL, Underwood J. Clinical, educational, and epidemiological value of autopsy. Lancet 2007; 369: 1471–1480.
40 Shojania KG, Burton EC. The vanishing nonforensic autopsy. N Engl J Med 2008; 358: 873–875.
41 Niederle MB, Niederle B. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist 2011; 16: 602–613.
42 Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011; 396: 273–298.
43 Öberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 2011; 30(Suppl 1): 3–7.
44 Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26: 805–818.
45 Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozgov I, Chan AK et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655–2664.